Company News

Latest News

Polaris Group’s Board Approves Private Placement at a Price Near Market Value
2025/12/29-Polaris Group (TWSE: 6550) convened an extraordinary shareholders’ meeting on the morning...
Read more »
Phase 1 Clinical Trial Results of ADI-PEG 20 in Acute Myeloid Leukemia by Polaris Group
Polaris Group (TWSE: 6550) is pleased to announce that its lead drug pegargiminase (ADI-PEG 20) which...
Read more »
GENOVIOR, Key Subsidiary of the Company Expands Sterile Injection Capacity to Supply Fully Synthetic Peptides & Specialty Injectables Globally
Genovior Biotech (“Genovior”) announced today the expansion of its sterile injectable manufacturing capacity,...
Read more »
GENOVIOR, Key Subsidiary of the Company and MNR Therapeutics announce an non-exclusive agreement for the commercialization of Fulvestrant in the Gulf Cooperation Council (GCC) region.
2025/11/21-GENOVIOR and MNR Therapeutics announce an non-exclusive agreement for the commercialization...
Read more »
Polaris Group’s Biologic License Application (BLA) for Pegargiminase (ADI-PEG 20) has officially entered the FDA substantive review stage.
2025/8/18-Polaris Group (The Company, TWSE:6550) previously adopted a rolling submission approach for...
Read more »
Polaris Group Announces Subsidiary PPI In-Licensing Exclusive Partnership with Bioprofarma Bagó to introduce ADI-PEG20, an innovative First-in-Class arginine degradation for hard-to-treat cancers in Argentina and other LATAM markets
2025/7/22-Polaris Group (TWSE:6550) announces its US California subsidiary Polaris Pharmaceuticals Inc....
Read more »
1 2 3 … 6
Scroll to Top
This site is registered on wpml.org as a development site.